635722-83-7

Usage

Molecular structure

1-Piperidinecarboxylic acid, 3-[[(1,1-dimethylethoxy)carbonyl]amino]-, 9H-fluoren-9-ylmethyl ester is a complex molecule that consists of a piperidine ring, a fluorenyl group, and a carbamate ester functional group.

Functional groups

The molecule contains a carbamate functional group attached to the piperidine carboxylic acid, which contributes to its reactivity and potential use in organic synthesis.

Stability

The presence of the fluorenyl group increases the molecule's stability, making it a useful building block for more complex organic molecules.

Potential applications

The compound has potential applications in drug development and as a building block for more complex organic molecules due to its unique structure and properties.

Need for further study

The precise properties and potential uses of 1-Piperidinecarboxylic acid, 3-[[(1,1-dimethylethoxy)carbonyl]amino]-, 9H-fluoren-9-ylmethyl ester would need to be studied further to fully understand its potential and limitations.

Upstream product

• 4129-17-3 diphenylphosphoranyl azide 
• 144-55-8 sodium hydrogencarbonate 
• 158922-07-7 Fmoc-nipecotic acid 
• 75-65-0 tert-butyl alcohol 

Downstream Products

• 184637-48-7 t-butyl piperidin-3-ylcarbamate 

Relevant academic research and scientific papers

PREVENTIVE OR THERAPEUTIC AGENTS FOR MULTIPLE SCLEROSIS

The preventive or therapeutic agents of the present invention for multiple sclerosis comprise compounds represented by the following formula (I), or salts or hydrates thereof, [wherein, T1, X, Z1, Z2, and R1 have the same meaning as T1, X, Z1, Z2, and R1 in this application].

COMBINATION DRUG

The present invention provides pharmaceutical agents comprising a dipeptidyl peptidase IV (DPPIV) inhibitor and a biguanide agent in combination, which enhance the effects of active circulating glucagon-like peptide-1 (GLP-1) and/or active circulating glucagon-like peptide-2 (GLP-2).

Condensed imidazole derivatives

The present invention is related to compounds represented by the following formula, or salts or hydrates thereof wherein, T1 represents a 4- to 12-membered heterocyclic group containing one or two nitrogen atoms in the ring, which is a monocyclic or bicyclic structure that may have one or more substituents; X represents a C1-6 alkyl group which may have one or more substituents, or such; Z1 and Z2 each independently represent a nitrogen atom or a group represented by the formula —CR2—; R1 and R2 independently represent a hydrogen atom, a C1-6 alkyl group which may have one or more substituents, or a C1-6 alkoxy group which may have one or more substituents, or such. These are novel compounds that exhibit an excellent DPPIV-inhibiting activity.